SCN1A and epilepsy: Predicting candidate compounds for epilepsy based upon their ability to affect the function of sodium channel protein Type 1 subunit alpha (the protein product of SCN1A) yields a recall (from amongst all ASMs, the fraction predicted to be effective) of 35% and precision (from amongst all drugs predicted to be effective, the fraction that are ASMs) of 32%, which equates to an F-score (harmonic mean of the precision and recall) of 33%.